<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="761">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 29, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324463</url>
  </required_header>
  <id_info>
    <org_study_id>PHRI.ACT.COVID19</org_study_id>
    <nct_id>NCT04324463</nct_id>
  </id_info>
  <brief_title>Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial</brief_title>
  <acronym>ACT COVID19</acronym>
  <official_title>Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ACT is a randomized clinical trial to assess therapies to reduce the clinical progression of
      COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ACT COVID-19 program consists of two parallel trials evaluating treatments for COVID-19
      in outpatients and inpatients who have tested positive for COVID-19. In the outpatient study,
      the combination of chloroquine with azithromycin will be evaluated to see if this treatment
      can prevent deterioration leading to hospital admission. For inpatients, the combination of
      chloroquine with azithromycin, as well as interferon beta-1b, will be evaluated to see if it
      can prevent admission to intensive care, mechanical ventilation and/or death.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, parallel group randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outpatients: Hospital Admission or Death</measure>
    <time_frame>Up to 6 weeks post randomization</time_frame>
    <description>In outpatients with COVID-19, the occurrence of hospital admission or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inpatients: Invasive mechanical ventilation or mortality</measure>
    <time_frame>Up to 6 weeks post randomization</time_frame>
    <description>Patients intubated or requiring imminent intubation at the time of randomization will only be followed for the primary outcome of death.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Coronavirus</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <arm_group>
    <arm_group_label>AZCT (Azithromycin plus hydroxychloroquine or chloroquine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Outpatients:
Hydroxychloroquine (400 mg twice daily for 7 days) or Chloroquine (500 mg twice daily for 7 days) plus Azithromycin (500 mg on day 1 followed by 250 mg daily for 4 days)
Inpatients:
Hydroxychloroquine (Two loading doses of 800 mg given 6 hours apart starting on day 1 followed by 400 mg twice daily for 7 days starting 6 hours after the second loading dose) or Chloroquine (Two loading doses of 1000 mg given 6 hours apart starting on day 1 followed by 500 mg twice daily for 7 days starting 6 hours after the second loading dose) plus Azithromycin (500 mg on day 1 followed by 250 mg daily for 4 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care (Control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Outpatients and Inpatients: No constraints for treating physicians on the therapies within the standard of care arm. All key co-interventions will be documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZCT plus Interferon Beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inpatients Only:
Hydroxychloroquine (Two loading doses of 800 mg given 6 hours apart starting on day 1 followed by 400 mg twice daily for 7 days starting 6 hours after the second loading dose) or Chloroquine (Two loading doses of 1000 mg given 6 hours apart starting on day 1 followed by 500 mg twice daily for 7 days starting 6 hours after the second loading dose) plus Azithromycin (500 mg on day 1 followed by 250 mg daily for 4 days) plus Interferon Beta (0.25 mg subcutaneous injection on days 1, 3, 5, and 7).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon Beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inpatients Only:
Interferon Beta (0.25 mg subcutaneous injection on days 1, 3, 5, and 7).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>oral medication</description>
    <arm_group_label>AZCT (Azithromycin plus hydroxychloroquine or chloroquine)</arm_group_label>
    <arm_group_label>AZCT plus Interferon Beta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydoxychloroquine or Chloroquine</intervention_name>
    <description>oral medication</description>
    <arm_group_label>AZCT (Azithromycin plus hydroxychloroquine or chloroquine)</arm_group_label>
    <arm_group_label>AZCT plus Interferon Beta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-Beta</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>AZCT plus Interferon Beta</arm_group_label>
    <arm_group_label>Interferon Beta</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Outpatients and Inpatients):

          -  Age ≥ 18 years of age

          -  Informed consent

          -  COVID-19 confirmed by established testing

        Exclusion Criteria (Outpatients):

          -  Contra-indication to azithromycin or chloroquine: allergy to study interventions, use
             of hydroxychloroquine or chloroquine within the past 3 months, known
             glucose-6-phosphate dehydrogenase (G6PD) deficiency, epilepsy, serious hearing or
             visual problems, advanced liver disease, at risk of malignancy arrhythmias, pregnancy
             (known or potential) or lactation

          -  Already receiving hydroxychloroquine or chloroquine or azithromycin

        Exclusion Criteria (Inpatients):

          -  Contra-indication to chloroquine, azithromycin or interferon ß: allergy to study
             interventions, use of hydroxychloroquine or chloroquine within the past 3 months,
             known G6PD, epilepsy, serious hearing or visual problems, at risk of malignant
             arrhythmias, pregnancy (known or potential) or lactation, advanced liver disease,
             known monoclonal gammopathy, history of severe depression or anxiety

          -  Already receiving hydroxychloroquine or chloroquine or azithromycin or interferon beta
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Whitlock, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilie Belley-Cote, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ACT COVID-19 Study Coordinator</last_name>
    <phone>905-297-3479</phone>
    <email>ACT.ProjectTeam@PHRI.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ACT COVID-19 Study Coordinator</last_name>
      <email>ACT.ProjectTeam@PHRI.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>chloroquine</keyword>
  <keyword>azithromycin</keyword>
  <keyword>coronavirus</keyword>
  <keyword>interferon</keyword>
  <keyword>hydroxychloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

